ATAC
LIVE

Serial Number

88439354

Owner

Heidelberg Pharma Research GmbH

Attorney

Todd A. Sullivan

Filing Date

May 21, 2019

Add to watchlist:

No watchlists yet
View on USPTO

ATAC Trademark

Serial Number: 88439354 • Registration: 6886783

ATAC is a trademark filed by Heidelberg Pharma Research GmbH on May 21, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Heidelberg Pharma Research GmbH (3 trademarks)

Gregor-Mendel Straße 22
Ladenburg 68526 , DE

Entity Type: 99

Trademark Details

Filing Date

May 21, 2019

Registration Date

November 1, 2022

Published for Opposition

August 16, 2022

Goods & Services

Pharmaceutical preparations, namely, anti-cancer and immunosuppression preparations; pharmaceuticals, namely, anti-cancer and immunosuppression preparations; chemico-pharmaceutical preparations, namely, chemical preparations for medical purposes for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances, namely, pharmaceutical products for the treatment of cancer and immunosuppression; pharmaceutical preparations, namely, anti-cancer preparations for veterinary use; chemical preparations for pharmaceutical purposes, namely, chemical preparations for the treatment of cancer and immunosupression; pharmaceutical preparations for human use, namely, pharmaceutical preparations for human use in the treatment of cancer and immnunosupression; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for use in oncology; diagnostic preparations for medical purposes; diagnostic agents for pharmaceutical use; diagnostic agents for medical use; diagnostic preparations for veterinary purposes; clinical diagnostic reagents for medical use; diagnostic chemical reagents for medical use; anti-cancer drugs, namely, anti-cancer preparations; pharmaceutical compounds for treating cancer and immunosuppression; anti-cancer preparations; anti-cancer preparations of chemical origin; biopharmaceuticals, namely, anti-cancer preparations for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics; antibodies being pharmaceutical preparations for the treatment of cancer and immunosuppression; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression with agents including amatoxin

Pharmaceutical advice; pharmaceutical consultation services; consultancy and information services relating to pharmaceutical products; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression

Pharmaceutical research services; medical and pharmacological research services; pharmaceutical products development; development of pharmaceutical preparations and medicines; consultancy relating to pharmaceutical research and development; provision of medical research services; scientific research; medical research; biomedical research services; research relating to biotechnology; research on the subject of pharmaceuticals; consultancy relating to research in the field of pharmacogenetics; research and development in the pharmaceutical and biotechnology fields; research and development in the field of diagnostic preparations; research and development in the field of biotechnology; pharmaceutical research and development for the pharmaceutical industry; research and development services in the field of antibody technology; research and development services in the field of antibodies; scientific laboratory services relating to the production of monoclonal antibodies; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 4, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 4, 2025 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Feb 4, 2025 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 4, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 4, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 4, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 4, 2025 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 1, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 1, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 16, 2022 NPUB
PUBLISHED FOR OPPOSITION
Aug 16, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 27, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 8, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 6, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 5, 2022 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 5, 2022 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 13, 2022 GNFN
FINAL REFUSAL E-MAILED
Jan 13, 2022 GNFR
FINAL REFUSAL WRITTEN
Jan 13, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 29, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 29, 2021 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 15, 2021 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 5, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 5, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 5, 2021 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 25, 2021 RCCK
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 5, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 5, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 5, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 5, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 5, 2021 COAR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 7, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 7, 2020 GNSL
SUSPENSION LETTER WRITTEN
Dec 7, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 4, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 4, 2020 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 25, 2020 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Nov 23, 2020 GNS2
INQUIRY TO SUSPENSION E-MAILED
Nov 23, 2020 GNSI
SUSPENSION INQUIRY WRITTEN
Nov 23, 2020 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 2, 2020 RCCK
ASSIGNED TO LIE
Nov 2, 2020 ALIE
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 26, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 26, 2020 GNSL
SUSPENSION LETTER WRITTEN
Feb 26, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 11, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 10, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 10, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 9, 2019 GNRN
NON-FINAL ACTION E-MAILED
Aug 9, 2019 GNRT
NON-FINAL ACTION WRITTEN
Aug 9, 2019 CNRT
ASSIGNED TO EXAMINER
Aug 8, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 5, 2019 NWOS
NEW APPLICATION ENTERED
May 24, 2019 NWAP